Fruquintinib as post-standard third-line therapy in a patient with mCRC without targetable mutations: a real-world application of FRESCO trial principles.

Interpreting MRD results and integrating assays into practice.

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Practical approach to MRD testing in breast cancer: Q&A.

MRD testing across the continuum of care.

Addressing late detection of systemic relapse, the clinical blind spot.

Fruquintinib as post-standard third-line therapy in a patient with mCRC without targetable mutations: a real-world application of FRESCO trial principles.

Interpreting MRD results and integrating assays into practice.

Targeting BRAF V600E mutations in metastatic colorectal cancer.

Practical approach to MRD testing in breast cancer: Q&A.

MRD testing across the continuum of care.

Addressing late detection of systemic relapse, the clinical blind spot.